Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 23, 2009

View Archived Issues

Phase II data support antitumor activity of tasisulam in platinum-resistant ovarian cancer

Preliminary results reported from first-in-human study of FP-1039

AT-13387 shows promising antitumor activity in mouse xenograft models

Medivir reports results from third quarter of 2009

Solvay reports results from the third quarter of 2009

HairDX launches HairDX (RxR) genetic test to assess risk for BPH and response to finasteride

Asuragen and Life Technologies to develop and distribute diagnostic test for CML

FDA grants priority review to Actelion's sNDA for miglustat in NP-C

Afexa Life Sciences starts clinical trial of LIP-01 for reducing blood lipids

AdCD40L immunotherapy for bladder cancer deemed safe in phase I/IIa trials

ATI-2042 effective at reducing atrial fibrillation burden in phase II trial

Atorvastatin improves eGFR regardless of metabolic syndrome state in CHD patients

Roche reports results from phase III trial of tocilizumab in sJIA

Merck & Co. describes CGRP receptor antagonists for the treatment of migraine

Vitae discloses 11beta-HSD1 inhibitors for the treatment of diabetes

Novel protease inhibitors in development at Enanta for the treatment of HCV infections

Seton Hall University presents D1 antagonists as antiepileptic agents

Sirona Biochem reports results from phase III trial of dapagliflozin in diabetes type 2

Taisho developing GlyT-1 inhibitors for the treatment of schizophrenia

Adamas expands phase II AAVID-1 clinical trial of TCAD therapy for influenza

Myriad reports initial results from ongoing phase IIa trial of Azixa in metastatic melanoma

Circassia reports results from phase II clinical trial of ToleroMune cat allergy therapy

European CHMP recommends approval of Merck & Co.'s fertility treatment Elonva

FDA approves Pfizer's Revatio injection for pulmonary arterial hypertension

FDA approves Abilify for indication in pediatric patients

FDA approves Pfizer's Geodon capsules as adjunctive treatment for bipolar disorder

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...